Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cct.2020.106176 http://scihub22266oqcxt.onion/10.1016/j.cct.2020.106176 33045402!7547023!33045402     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33045402&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Contemp+Clin+Trials 2021 ; 100 (?): 106176 Nephropedia Template TP {{tp|p=33045402|t=2021. The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design |pdf=|usr=}}{{33045402}} gab.com Text The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design JO: Contemp Clin Trials http://www.kidney.de/pget.php?&tw=1&pmid=33045402 #FOAvip OBJECTIVES: To determine the effect of vitamin D supplementation on disease progression and post-exposure prophylaxis for COVID-19 infection. We hypothesize that high-dose vitamin D3 supplementation will reduce risk of hospitalization/death among those with recently diagnosed COVID-19 infection and will reduce risk of COVID-19 infection among their close household contacts. METHODS: We report the rationale and design of a planned pragmatic, cluster randomized, double-blinded trial (N = 2700 in total nationwide), with 1500 newly diagnosed individuals with COVID-19 infection, together with up to one close household contact each (~1200 contacts), randomized to either vitamin D3 (loading dose, then 3200 IU/day) or placebo in a 1:1 ratio and a household cluster design. The study duration is 4 weeks. The primary outcome for newly diagnosed individuals is the occurrence of hospitalization and/or mortality. Key secondary outcomes include symptom severity scores among cases and changes in the infection (seroconversion) status for their close household contacts. Changes in vitamin D 25(OH)D levels will be assessed and their relation to study outcomes will be explored. CONCLUSIONS: The proposed pragmatic trial will allow parallel testing of vitamin D3 supplementation for early treatment and post-exposure prophylaxis of COVID-19. The household cluster design provides a cost-efficient approach to testing an intervention for reducing rates of hospitalization and/or mortality in newly diagnosed cases and preventing infection among their close household contacts. Twit Text FOAVip The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design ????Contemp Clin Trials http://www.kidney.de/pget.php?&tw=1&pmid=33045402 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33045402 #FOAvip English Wikipedia <ref>{{Cite pmid|33045402}}</ref> The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design #MMPMID33045402 Wang R; DeGruttola V; Lei Q; Mayer KH; Redline S; Hazra A; Mora S; Willett WC; Ganmaa D; Manson JE Contemp Clin Trials 2021[Jan]; 100 (?): 106176 PMID33045402show ga OBJECTIVES: To determine the effect of vitamin D supplementation on disease progression and post-exposure prophylaxis for COVID-19 infection. We hypothesize that high-dose vitamin D3 supplementation will reduce risk of hospitalization/death among those with recently diagnosed COVID-19 infection and will reduce risk of COVID-19 infection among their close household contacts. METHODS: We report the rationale and design of a planned pragmatic, cluster randomized, double-blinded trial (N = 2700 in total nationwide), with 1500 newly diagnosed individuals with COVID-19 infection, together with up to one close household contact each (~1200 contacts), randomized to either vitamin D3 (loading dose, then 3200 IU/day) or placebo in a 1:1 ratio and a household cluster design. The study duration is 4 weeks. The primary outcome for newly diagnosed individuals is the occurrence of hospitalization and/or mortality. Key secondary outcomes include symptom severity scores among cases and changes in the infection (seroconversion) status for their close household contacts. Changes in vitamin D 25(OH)D levels will be assessed and their relation to study outcomes will be explored. CONCLUSIONS: The proposed pragmatic trial will allow parallel testing of vitamin D3 supplementation for early treatment and post-exposure prophylaxis of COVID-19. The household cluster design provides a cost-efficient approach to testing an intervention for reducing rates of hospitalization and/or mortality in newly diagnosed cases and preventing infection among their close household contacts. |*COVID-19 Drug Treatment[MESH] |*Dietary Supplements[MESH] |*Vitamin D/therapeutic use[MESH] |Adult[MESH] |COVID-19/mortality[MESH] |Comorbidity[MESH] |Double-Blind Method[MESH] |Hospitalization/statistics & numerical data[MESH] |Humans[MESH] |Middle Aged[MESH] |Minority Groups/statistics & numerical data[MESH] |Pragmatic Clinical Trials as Topic[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH] |Seroconversion[MESH] |Severity of Illness Index[MESH]The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomiz(epmc).pdf DeepDyve Pubget Overpricing